April 15 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA IN PHASE 2A CLINICAL TRIAL
HOTH THERAPEUTICS INC - PATIENTS EXPERIENCED A 50% REDUCTION IN PRURITUS SEVERITY, WITH MEAN SCORES DROPPING FROM 1.6 ON DAY 1 TO 0.8 BY DAY 21
HOTH THERAPEUTICS INC - HT-001 WAS WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED
Source text: ID:nPn7mLV8ha
Further company coverage: HOTH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.